NASDAQ · Biotechnology
CRNX (CRNX) Stock
$83.81
-0.09%
NASDAQ: CRNX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Motley Fool · Jul 13, 2026
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
MarketBeat · Jul 11, 2026
Why This Pharmaceutical Stock Jumped Close to 100% This Week
Motley Fool · Jul 10, 2026
Why Crinetics Stock Soared 99% This Week
24/7 Wall St. · Jul 9, 2026
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
MT Newswires · Jul 8, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held1.59%
Institutions Held119.81%
Institutions Float Held121.75%
Peer Comparison
About CRNX
CRNX is led by CEO R. Scott Struthers, employs 594 people, headquartered in San Diego, US, publicly traded since 2018.
CRNX stock trades at $83.81 with a market capitalization of $8.87B. The stock is valued at a price-to-earnings (P/E) ratio of -8.57, price-to-book of 3.56, price-to-sales of 215.38. Over the past 52 weeks the stock has ranged between $25.83 and $83.93, and currently trades at its 52-week high.
On profitability, CRNX generates a return on equity (ROE) of -39.17%, return on capital employed of -52.12%, an operating margin of -13.08%, a net profit margin of -27.47%.